What Terumo Neuro does

Terumo Neuro, founded in 1997 and headquartered in Tustin, California, is a wholly owned subsidiary of Japan's Terumo Corporation (TSE: 4543.T) that develops catheter-based neuroendovascular medical devices for the treatment of cerebral aneurysms, hemorrhagic and ischemic stroke, and carotid artery disease. The company sells its devices to hospitals with neurointerventional surgical suites and to neurosurgeons and interventional neurologists, operating across North America, EMEA, China/APAC, and LATAM through direct field sales.

The product portfolio spans three solution areas: therapeutic devices (FRED X flow diverter, WEB/WovenEndoBridge intrasaccular embolization system, HydroCoil hydrogel embolic coils, Bare Platinum Coils, LVIS EVO stent, BOBBY balloon guide catheters, aspiration catheters, stentrievers, and carotid stents), and access products (specialized catheters and guidewires). Core technologies include proprietary flow diversion architectures, intrasaccular braided devices, hydrogel-based coil expansion for aneurysm occlusion, and balloon guide catheter systems — all backed by an expanding clinical evidence base highlighted by the landmark RAGE study (750+ patients at 45 North American sites) demonstrating 86% adequate occlusion and 0.5% rebleeding rates for HydroCoil in ruptured intracranial aneurysms.

The business model is a classic enterprise medical device hardware-sales motion: devices are sold through quote-based contracts directly to hospitals via field sales representatives and inside sales teams, with regional websites and participation in industry congresses (SNIS, ESMINT) supporting physician engagement. Revenue is generated entirely through hardware unit sales across a globally distributed customer base. Leadership is headed by President and CEO Carsten Schroeder, with functional heads covering commercial operations, clinical research, scientific affairs/CMO, regulatory, supply chain, R&D, and people.

Name

Terumo Neuro

Legal name

Terumo Neuro

Website

https://microvention.com

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Terumo Neuro, a wholly owned subsidiary of Terumo Corporation (formerly MicroVention), develops catheter-based neurovascular medical devices for treating cerebral aneurysms, hemorrhagic and ischemic stroke, and carotid artery disease, selling flow diverters, embolic coils, stentrievers, and access products directly to hospitals globally.

Ownership category

akta.pro rank

Product category

Neurovascular Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

Keywords

• Neurovascular medical devices
• Flow diversion technology
• Aneurysm embolization devices
• Ischemic stroke treatment
• Neurovascular catheters

Headquarters

HQ city

Tustin

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Neurovascular Medical Device Sales: Terumo Neuro generates revenue through the sale of neurovascular medical devices including flow diverters, embolic coils, stentrievers, aspiration catheters, and access products to hospitals and healthcare providers treating stroke patients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Terumo Neuro develops and manufactures catheter-based neuroendovascular medical devices for the treatment of cerebral aneurysms and other neurovascular diseases. The company's portfolio covers three solution areas: Hemorrhagic (flow diverters, intrasaccular devices, embolic coils), Ischemic (aspiration catheters, stentrievers, carotid stents), and Access (catheters and guidewires). Products are sold directly to hospitals, neurosurgeons, and interventional neurologists globally.

Product overview

Terumo Neuro offers a comprehensive neurovascular portfolio organized across three main solution areas: Hemorrhagic (devices to treat or prevent hemorrhagic stroke including aneurysm treatment and neurovascular malformations), Ischemic (devices for ischemic stroke and carotid artery disease including aspiration catheters, stentrievers, and carotid stents), and Access (catheters and guidewires for gaining access to treatment areas). The featured therapeutic products include FRED™ X flow diverter, WEB™ Embolization System (WovenEndoBridge), HydroCoil™ Embolic System (hydrogel coils), BOBBY™ Balloon Guide Catheters, Bare Platinum Coils, LVIS EVO Stent, aspiration catheters, stentrievers, and carotid stents. The access portfolio includes specialized catheters and guidewires. Terumo Neuro operates as a wholly owned subsidiary of Terumo Corporation (formerly MicroVention) and serves the global neurovascular market with products backed by robust clinical data.

Differentiator

Problem solved

Functional benefit

Brands

• FRED X: Flow diverter for aneurysm treatment
• WEB Embolization System
• BOBBY
• HydroCoil Embolic System
• WovenEndoBridge
• LVIS EVO Stent
• FRED X Flow Diverter

Products and services

• FRED X Flow Diverter Flow diverter device representing the next advancement in flow diversion technology for treating intracranial aneurysms, used by neurosurgeons and interventional neuroradiologists at hospitals.
• WEB Embolization System (WovenEndoBridge) Intrasaccular device for aneurysm embolization treatment. The WovenEndoBridge 17 system is approved in Japan for treating ruptured aneurysms with over 15 years of clinical data, used by neurosurgeons for complex aneurysm cases.
• HydroCoil Embolic System (Hydrogel Coils) Hydrogel coils for aneurysm embolization that achieved 86% adequate occlusion rate and 0.5% rebleeding rate in the RAGE study for treating ruptured intracranial aneurysms at hospitals performing neurointerventional procedures.
• BOBBY Balloon Guide Catheters Balloon guide catheters designed for neurovascular intervention procedures to assist in aneurysm treatment and stroke interventions at hospitals.
• Bare Platinum Coils Standard platinum coils for aneurysm embolization, part of Terumo Neuro's comprehensive hemorrhagic stroke treatment portfolio for hospitals and neurosurgeons.
• LVIS EVO Stent Stent used in aneurysm treatment, included in the Aneurysm Treatment Alliance portfolio for hospitals in Europe, Middle East, and Africa.
• Aspiration Catheters Catheters for ischemic stroke treatment using aspiration technology to remove blood clots and restore blood flow to the brain at hospitals performing acute stroke interventions.
• Stentrievers Stent-based clot retrieval devices for ischemic stroke treatment that capture and remove blood clots from cerebral arteries at stroke centers.
• Carotid Stents Stents for treating carotid artery disease and preventing stroke by maintaining blood flow through narrowed or blocked carotid arteries at vascular intervention centers.
• Access Catheters Specialized catheters that allow physicians to gain access to the treatment area during neurovascular intervention procedures at hospitals.
• Guidewires Guidewires designed for neurovascular procedures to provide navigation and support for catheter placement during treatment at hospitals and stroke centers.

Quantifiable outcome

• 86% adequate occlusion rate for ruptured intracranial aneurysms treated with HydroCoil Embolic System
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• European Physicians (EMEA)coreStrategic or Co-development Partner · 3 September 2025Terumo Neuro launched the Aneurysm Treatment Alliance initiative at the 2025 ESMINT Annual Congress in Marseille, France. The Alliance provides standardized tools and a collaborative platform for physicians across Europe, Middle East, and Africa. The platform features products including WEB Device, LVIS EVO Stent, FRED X Flow Diverter, Hydrogel Coils, and Bare Platinum Coils for aneurysm treatment, reflecting Terumo Neuro's focused commitment to physician partnerships.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Stryker (Neurovascular): Stryker's Neurovascular division (acquired through the purchase of Target Therapeutics/Codman) directly competes with Terumo Neuro in coils, flow diverters, stentrievers, and access catheters for hemorrhagic and ischemic stroke treatment, serving the same hospital customers.
• Medtronic (Neurovascular): Medtronic's Neurovascular business (formerly Covidien) competes with Terumo Neuro across coils, flow diversion, stentrievers, and access products for cerebral aneurysm and stroke interventions, targeting the same neurosurgical and interventional neurology customers.
• Penumbra: Penumbra is a direct competitor in the neurovascular space, particularly strong in aspiration catheters for ischemic stroke and increasingly expanding into coils and embolization, directly overlapping with Terumo Neuro's therapeutic portfolio.
• Cerenovus (Johnson & Johnson MedTech): Cerenovus, J&J's neurovascular business, directly competes with Terumo Neuro across coils, flow diverters, stentrievers, and access products for hemorrhagic and ischemic stroke treatment, with comparable enterprise sales motion to hospitals.
• Balt (BALT Group): Balt is a privately held neurovascular company that directly competes with Terumo Neuro in coils, flow diverters, and liquid embolic systems for the treatment of cerebral aneurysms and AVMs across European and global markets.

Broad incumbents

• Integra LifeSciences: Integra LifeSciences has a broader portfolio in neurosurgery and neurocritical care but overlaps with Terumo Neuro in certain neurovascular access and dural repair products, addressing overlapping hospital customers though with a wider product breadth.

Emerging players

• Rapid Medical: Rapid Medical is an emerging neurovascular company developing adjustable stentrievers and flow diverters, competing with Terumo Neuro in select ischemic and hemorrhagic stroke device categories with differentiated technology.
• Phenox: Phenox is a Germany-based neurovascular company offering flow diverters and stent retrievers that compete with Terumo Neuro's FRED X and stentriever products, with particular strength in the European market.
• Wallaby Medical: Wallaby Medical is an emerging neurovascular player developing stent retrievers, aspiration catheters, and access devices that compete with portions of Terumo Neuro's ischemic stroke and access product portfolios.
• MicroPort Scientific Corporation: MicroPort Scientific has a neurovascular business that competes with Terumo Neuro in flow diverters and related neurointerventional devices, particularly in Asia-Pacific markets where Terumo Neuro is expanding.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/terumoneuro
• YouTubeyoutube.com/channel/UCZs9HfH01BZMdTtMelJyH4g
• LinkedInlinkedin.com/company/microvention
• Instagraminstagram.com/terumoneuro

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds5 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Terumo Neuro